[1]吴仁瑞,汪 琛,刘 超.紫杉醇联合卡铂方案同步放化疗在Ⅲ期胃食管结合部癌中的近期疗效和安全性[J].医学信息,2022,35(20):52-55.[doi:10.3969/j.issn.1006-1959.2022.20.012]
　WU Ren-rui,WANG Chen,LIU Chao.Short-term Efficacy and Safety of Concurrent Chemoradiotherapy with Paclitaxel and Carboplatin in Stage Ⅲ Gastroesophageal Junction Cancer[J].Journal of Medical Information,2022,35(20):52-55.[doi:10.3969/j.issn.1006-1959.2022.20.012]
点击复制

紫杉醇联合卡铂方案同步放化疗在Ⅲ期胃食管结合部癌中的近期疗效和安全性()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年20期
页码:
52-55
栏目:
论著
出版日期:
2022-10-15

文章信息/Info

Title:
Short-term Efficacy and Safety of Concurrent Chemoradiotherapy with Paclitaxel and Carboplatin in Stage Ⅲ Gastroesophageal Junction Cancer
文章编号:
1006-1959（2022）20-0052-04
作者:
吴仁瑞; 汪 琛; 刘 超
（赣州市人民医院肿瘤科，江西 赣州 341000）
Author(s):
WU Ren-rui; WANG Chen; LIU Chao
(Department of Oncology,Ganzhou People’s Hospital,Ganzhou 341000,Jiangxi,China)
关键词:
胃食管结合部癌; 紫杉醇; 卡铂; 同步放化疗; 应激反应
Keywords:
Gastroesophageal junction carcinoma; Paclitaxel; Carboplatin; Concurrent chemoradiotherapy; Stress response
分类号:
R735.2
DOI:
10.3969/j.issn.1006-1959.2022.20.012
文献标志码:
A
摘要:
目的 探讨紫杉醇联合卡铂方案同步放化疗在Ⅲ期胃食管结合部癌中的近期疗效和安全性。方法 选择2019年8月-2021年10月赣州市人民医院收治的Ⅲ期胃食管结合部癌患者76例，根据随机数字表法分为研究组和对照组，每组38例。对照组给予紫杉醇+替吉奥单纯化疗方案治疗，研究组给予紫杉醇+卡铂同步放化疗方案。比较两组治疗前（T0）、治疗1个疗程后（T1）、治疗3个疗程后（T2）皮质醇（COR）、丙二醛（MDA）、神经元特异性烯醇化酶（NSE）、癌胚抗原（CEA）、R0切除率、淋巴结阳性率、病理分期降期率、近期疗效及用药安全性。结果 两组T1、T2时MDA水平低于T0，且研究组低于对照组（P＜0.05）；两组T1、T2时COR水平高于T0，但研究组低于对照组（P＜0.05）；两组T1、T2时NSE、CEA水平低于T0，且研究组低于对照组（P＜0.05）；研究组R0切除率、淋巴结阳性率、病理分期降期率均高于对照组（P＜0.05）；研究组DCR、RR均高于对照组（P＜0.05）；研究组药物毒副反应发生率与对照组比较，差异无统计学意义（P＞0.05）。结论 Ⅲ期胃食管结合部癌中联合应用紫杉醇与卡铂方案同步放化疗的近期疗效理想，可减轻机体术后应激反应，降低肿瘤标志物水平，且不会大幅增加药物毒副作用，安全性较高。
Abstract:
Objective To investigate the short-term efficacy and safety of paclitaxel combined with carboplatin concurrent chemoradiotherapy in stage Ⅲ gastroesophageal junction cancer.Methods A total of 76 patients with stage Ⅲ gastroesophageal junction cancer admitted to Ganzhou People’s Hospital from August 2019 to October 2021 were selected and divided into study group and control group according to random number table method, with 38 cases in each group. The control group was treated with paclitaxel+tegafur chemotherapy alone, and the study group was treated with paclitaxel+carboplatin concurrent chemoradiotherapy. Cortisol (COR), malondialdehyde (MDA), neuron-specific enolase (NSE), carcinoembryonic antigen (CEA) before treatment (T0), after one course of treatment (T1) and after three courses of treatment (T2), R0 resection rate, lymph node positive rate, pathological stage downstaging rate, short-term efficacy and medication safety were compared between the two groups.Results The MDA levels at T1 and T2 in the two groups were lower than those at T0, and the study group was lower than the control group (P<0.05). The levels of COR at T1 and T2 were higher than those at T0, but the study group was lower than the control group (P<0.05). The levels of NSE and CEA at T1 and T2 in the two groups were lower than those at T0, and those in the study group were lower than the control group (P<0.05). The R0 resection rate, lymph node positive rate and pathological staging downstaging rate of the study group were higher than those of the control group (P<0.05). DCR and RR in study group were higher than those in control group (P<0.05). There was no significant difference in the incidence of adverse drug reactions between the study group and the control group (P>0.05).Conclusion The short-term efficacy of concurrent chemoradiotherapy with paclitaxel and carboplatin in stage Ⅲ gastroesophageal junction cancer is ideal, which can reduce the body’s postoperative stress response, reduce the level of tumor markers, and will not significantly increase drug side effects, with high safety.

参考文献/References:

[1]袁勇,陈心足,胡建昆,等.食管胃结合部腺癌外科治疗中国专家共识(2018年版)解读[J].中华胃肠外科杂志,2019,22(2):101-106.[2]李焱芳,陶芹,李韶华,等.卡培他滨辅助紫杉醇+顺铂化疗对胃癌患者cTnI、BNP的影响[J].现代消化及介入诊疗,2021,26(4):437-440. [3]Xu J,Bai Y,Xu N,et al.Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma[J].Clin Cancer Res,2020,26(17):4542-4550.[4]Nanashima A,Tominaga T,Nonaka T,et al.A case of multiple synchronous quadruple cancers of the stomach, sigmoid colon, rectum, and pancreas[J].Int J Surg Case Rep,2017,35:4-7.[5]史金明,李宁,赵东兵,等.局部晚期胃癌全新辅助治疗Ⅱ期临床研究中期分析[J].中华放射肿瘤学杂志,2021,30(10):1025-1029. [6]丁战伟,李志彬,郭银谋.胃癌根治术联合腹腔热灌注化疗治疗进展期胃癌的疗效与安全性评价[J].癌症进展,2020,18(23):2435-2438. [7]杨从容,王军,秦建军.NCCN食管和食管胃结合部癌临床实践指南2018 V1版主要更新点解读[J].中国胸心血管外科临床杂志,2018,25(8):650-653. [8]陈天武,曹金明.食管和食管-胃交界部癌AJCC第八版TNM分期指南更新解读[J].西部医学,2021,33(4):473-477. [9]苏卓彬,李曙光,任惠敏,等.紫杉醇联合卡铂单周化疗方案与奥沙利铂联合卡培他滨方案对Ⅲ期胃癌患者的疗效及安全性比较[J].中国医药,2020,15(10):1567-1571. [10]王晓娟,朱玥璐,崔成旭,等.局部进展期胃癌新辅助化疗两药与三药方案的比较[J].中国肿瘤临床与康复,2021,28(1):1-5.[11]王亚军,李松波,杨谦.紫杉醇脂质体联合卡培他滨治疗胃癌效果及对C-12多肿瘤标志物蛋白芯片水平的影响[J].中国药业,2020,29(18):75-78. [12]杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90,111.[13]Ohyama H,Yoshimura D,Hirotsu Y,et al.Rapidly declining trend of signet ring cell cancer of the stomach may parallel the infection rate of Helicobacter pylori[J].BMC Gastroenterol,2019,19(1):178.[14]彭涛,娄展,张育,等.紫杉醇联合卡铂新辅助化疗治疗Ⅲ期胃癌的疗效及安全性[J].现代肿瘤医学,2019,27(10):1765-1768. [15]苏卓彬,王国强,杨永江,等.胃癌细胞miR-30a的表达对紫杉醇联合卡铂新辅助化疗敏感性的影响[J].中国临床研究,2019,32(11):1466-1470,1475. [16]江承川,刘莎,赵惠萍,等.晚期胃癌患者行紫杉醇联合卡培他滨化疗效果及血清内皮抑素、VEGF变化研究[J].国际检验医学杂志,2019,40(10):1192-1196. [17]方玫玫,杨钰贤,李舟,等.晚期胃癌不同一线化疗方案治疗及生存分析[J].转化医学杂志,2019,8(2):89-94. [18]田园,王强,王军,等.新辅助同步放化疗联合手术对比直接手术治疗Siewert Ⅱ、Ⅲ型食管胃结合部腺癌随机对照试验的远期预后分析[J].中华胃肠外科杂志,2021,24(2):128-137. [19]陈华敏,吴煌福,黄光钺.卡培他滨辅助化疗治疗老年晚期胃癌50例疗效评价[J].中国药业,2018,27(7):44-46. [20]屈淑贤,邱佳宁,张译丹,等.紫杉醇脂质体联合卡培他滨与DCF方案治疗晚期胃癌近期疗效比较[J].中华肿瘤防治杂志,2019,26(11):790-793.[21]张漓,张靖,王渊,等.新辅助放化疗序贯方案治疗Ⅲ期食管癌的疗效[J].医学临床研究,2017,34(5):860-862. [22]曹铭富,彭涛,王国强,等.新辅助同步放化疗和单纯化疗在Ⅲ期食管胃结合部腺癌治疗中的应用对比观察[J].山东医药,2019,59(8):61-64. [23]Turner MA,Amirfakhri S,Nishino H,et al.A Patient-Derived Orthotopic Xenograft Model of Gastroesophageal-Junction Adenocarcinoma Translated to the Clinic by Tumor-Targeting Fluorescent Antibodies to Carcinoembryonic-Antigen-Related Cell-Adhesion Molecules[J].In Vivo,2021,35(4):1959-1963.[24]刘培根,颜璟,吴艳军,等.术前新辅助化疗治疗可切除局部晚期Siewert Ⅱ、Ⅲ型食管胃结合部腺癌效果分析[J].肿瘤研究与临床,2020,32(6):394-399. [25]刘广国,邓海军,罗文娟,等.局部晚期食管癌新辅助放化疗方案的临床疗效评价[J].现代消化及介入诊疗,2021,26(6):739-744. [26]Qubtia M,Ishaq Y,Munawar K,et al.Efficacy And Toxicity Of Carboplatin/Paclitaxel Based Chemoradiation For Localized Oesophageal Cancer[J].J Ayub Med Coll Abbottabad,2017,29(1):8-12.

相似文献/References:

[1]李思文,张 燕.不同紫杉醇剂型联合卡铂治疗卵巢癌的疗效研究[J].医学信息,2019,32(07):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
　LI Si-wen,ZHANG Yan.Therapeutic Effect of Different Paclitaxel Dosage Forms Combined With Carboplatin On Ovarian Cancer[J].Journal of Medical Information,2019,32(20):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
[2]王小毛,黄 晶,石 峰.金龙胶囊对耐紫杉醇及卡铂卵巢癌H08910细胞的逆转及增敏作用[J].医学信息,2020,33(04):94.[doi:10.3969/j.issn.1006-1959.2020.04.028]
　WANG Xiao-mao,HUANG Jing,SHI Feng.Reversion and Sensitization Effect of Jinlong Capsule on Paclitaxel and Carboplatin-resistant Ovarian Cancer H08910 Cells[J].Journal of Medical Information,2020,33(20):94.[doi:10.3969/j.issn.1006-1959.2020.04.028]
[3]李 博.紫杉醇加顺铂治疗晚期老年非小细胞癌的疗效[J].医学信息,2020,33(10):153.[doi:10.3969/j.issn.1006-1959.2020.10.045]
　LI Bo.Paclitaxel Plus Cisplatin in the Treatment of Advanced Elderly Non-small Cell Carcinoma[J].Journal of Medical Information,2020,33(20):153.[doi:10.3969/j.issn.1006-1959.2020.10.045]
[4]葛文军,宋继荣.紫杉醇联合洛铂在局部晚期宫颈癌患者术前新辅助化疗中的应用[J].医学信息,2020,33(13):106.[doi:10.3969/j.issn.1006-1959.2020.13.029]
　GE Wen-jun,SONG Ji-rong.Paclitaxel Combined with Lobaplatin in Neoadjuvant Chemotherapy for Patients with Locally Advanced Cervical Cancer[J].Journal of Medical Information,2020,33(20):106.[doi:10.3969/j.issn.1006-1959.2020.13.029]
[5]石少庆,宋丽丽.紫杉醇联合卡铂方案在三阴性乳腺癌新辅助化疗中的治疗效果及对患者病理变化的影响[J].医学信息,2023,36(02):145.[doi:10.3969/j.issn.1006-1959.2023.02.031]
　SHI Shao-qing,SONG Li-li.The Therapeutic Effect of Paclitaxel Combined with Carboplatin in Neoadjuvant Chemotherapy for Triple Negative Breast Cancer and its Effect on Pathological Changes[J].Journal of Medical Information,2023,36(20):145.[doi:10.3969/j.issn.1006-1959.2023.02.031]

更新日期/Last Update: 1900-01-01